DOSING REGIMEN FOR COMBINATION THERAPY TARGETING DLL3 AND PD-1

The present invention provides a method for the treatment of DLL3-positive cancer or SCLC, comprising administering to a subject in need thereof an anti-DLL3 agent and an anti-PD-1 antibody. Step dosing of the anti-DLL3 agent is also disclosed. La presente invención proporciona un método para tratar...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	MINOCHA Mukul, SMIT Marie - Ann Damiette, ROYCHOUDHURY Siddhartha, SHETTY Aditya, SADRAEI Nooshin Hashemi, WONG Hansen
Format:	Patent
Sprache:	eng ; spa
Schlagworte:	CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention provides a method for the treatment of DLL3-positive cancer or SCLC, comprising administering to a subject in need thereof an anti-DLL3 agent and an anti-PD-1 antibody. Step dosing of the anti-DLL3 agent is also disclosed. La presente invención proporciona un método para tratar el cáncer DLL3 positivo o el SCLC, que comprende administrar a un sujeto que lo necesite de un agente anti-DLL3 y un anticuerpo anti-PD-1. La dosis escalonada del agente anti-DLL3 también se divulga.